Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys plus lamivudine or entecavir versus no treatment in children with immune-tolerant chronic hepatitis B
MOH_2017-06-13_000517Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa, lamivudine and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Roche. Started Nov 2015; status: active, not recruiting.
02
Drugs
interferon alfalamivudineentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on MOH_2017-06-13_000517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-13_000517.